|
Volumn 4, Issue 4, 1999, Pages 413-417
|
Why angiogenesis inhibition? Commentary
|
Author keywords
Angiogenesis
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
OXYGEN;
ANTIANGIOGENIC ACTIVITY;
ANTIANGIOGENIC THERAPY;
ANTIBIOTIC THERAPY;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CANCER RESEARCH;
CANCER SURGERY;
CANCER SURVIVAL;
CANCER THERAPY;
CELL PROLIFERATION;
DISEASE FREE SURVIVAL;
DISTANT METASTASIS;
EFFECTOR CELL;
ENDOTHELIUM CELL;
HODGKIN DISEASE;
HUMAN;
LABELING INDEX;
MOLECULAR WEIGHT;
OVARY TUMOR;
OVERALL SURVIVAL;
PHENOTYPE;
PRIMARY TUMOR;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SMALL CELL LUNG CANCER;
SOLID TUMOR;
SURVIVAL RATE;
SURVIVAL TIME;
TESTIS TERATOMA;
TUMOR GROWTH;
TUMOR SUPPRESSOR GENE;
ANIMAL;
EXPERIMENTAL NEOPLASM;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
HUMANS;
NEOPLASMS;
NEOPLASMS, EXPERIMENTAL;
NEOVASCULARIZATION, PATHOLOGIC;
|
EID: 0033210822
PISSN: 11073756
EISSN: 1791244X
Source Type: Journal
DOI: 10.3892/ijmm.4.4.413 Document Type: Article |
Times cited : (3)
|
References (14)
|